Johnson & Johnson COVID-19 Vaccine Fully Approved by Health Canada to Prevent COVID-19 in Individuals 18 years and Older

Toronto ON, 24 November 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that Health Canada has approved its single-shot COVID-19 vaccine to prevent COVID-19 in individuals 18 years of age and older. This decision was based on scientific evidence, including initial data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination. “We are delighted by Health Canada’s decision to approve the Johnson &Johnson COVID-19 vaccine based on Phase 3 clinical data that proves the vaccine’s robust safety and efficacy,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research &Development, Johnson &Johnson. “As vaccination rates continue to climb, a vaccine that prevents severe disease and protects against COVID-related hospitalization and death will help ease the strain on healthcare systems and is an important option for people in Canada and around the world.”“Today marks the first major regulatory approval for the Johnson &Johnson COVID-19 vaccine and an important moment to recognize the dedication of everyone involved in our COVID-19 vaccine development, our partners, the regulators and clinical study participants. We are proud to have a COVID-19 vaccine available to protect people around the world and will continue t...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
AbstractLong-term sequel of acute COVID-19, commonly referred to as long COVID, has affected millions of patients worldwide. Long COVID patients display persistent or relapsing and remitting symptoms that include fatigue, breathlessness, cough, myalgia, arthralgia, sleep disturbance, cognitive impairment and skin rashes. Due to the shared clinical features, laboratory and imaging findings, long COVID could mimic rheumatic disease posing a diagnostic challenge. Our comprehensive literature review will help rheumatologist to be aware of long COVID manifestations and differentiating features from rheumatic diseases to ensure ...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
Source: Journal of Neurology - Category: Neurology Source Type: research
ConclusionA growing body of literature has shown an association between SARS ‐CoV‐2 infection and the development of different types of CNS demyelination. Although causality cannot readily be inferred, this review may suggest a probable causal relationship, through a para-infectious or post-infectious immune-mediated etiology in COVID-19 patients. This relationship needs to be clarified in future research.
Source: Journal of Neurology - Category: Neurology Source Type: research
Extra vaccine doses were expected to lower infection rates. But the shots also seem to be preventing severe illness caused by the new variant, the C.D.C. reported.
Source: NYT Health - Category: Consumer Health News Authors: Tags: your-feed-science Vaccination and Immunization Coronavirus (2019-nCoV) Coronavirus Omicron Variant Coronavirus Delta Variant Disease Rates Centers for Disease Control and Prevention United States Source Type: news
Postacute COVID syndrome, an ongoing inflammatory state following infection with SARS-CoV-2, is associated with greater risk of metabolic-associated fatty liver disease.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Infectious Diseases News Source Type: news
Data suggest that Black people are equally or more willing than White people to get a vaccine, which may mean access is the bigger problem, researchers say.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news
Arizona Gov. Doug Ducey is suing the Biden administration over its demand that the state stop sending millions in federal COVID-19 relief money to schools if they don’t have mask requirements or close due to COVID-19 outbreaks
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
March 5, 2021 - Johnson &Johnson (the Company) announced today that Health Canada has granted an Interim Order (IO) authorization for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson &Johnson, to prevent COVID-19 in individuals 18 years of age and older.This decision was based on scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.Johnson &Johnson anticipates...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
NEW BRUNSWICK, N.J., February 28, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson &Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). “For more than 130 years, Johnson &Johnson has come to the aid of people during times of crisis, and we believe tod...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Allergy & Immunology | Brain | Canada Health | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | Clinical Trials | Coronavirus | COVID-19 | Ebola | Ebola Vaccine | Health Management | Heart | Hypertension | Infectious Diseases | Learning | Legislation | Neurology | Neuroscience | Pharmaceuticals | Pulmonary Hypertension | SARS | Science | Study | Universities & Medical Training | Vaccines | Zika Virus